We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
French authorities are calling for the withdrawal of Anuh Pharma’s GMP certificate after an inspection turned up 24 alleged GMP deficiencies. Read More
An FDA audit of Indian drugmaker Lupin revealed four potential violations in two 483s at two of its production facilities, the company admitted in a note to the Bombay Stock Exchange Tuesday. Read More
The FDA slapped pharmaceutical manufacturer and repackager Safecor Health with a 13-item Form 483 citing lapses in quality control, batch specification and written procedures. Read More
There is a strong correlation between a surge in warning letters over data integrity issues and increased FDA inspections of manufacturers in India and China — one that could cause production headaches for U.S. drugmakers partnering with these facilities. Read More
Shortly after receiving an FDA warning letter for major quality deficiencies, Indian drugmaker was slammed for data integrity issues and GMP violations by the World Health Organization. Read More
The FDA has slapped hair and skincare products maker Alikay Naturals with a warning letter that takes the company to task for the presence of lead in one of its products. Read More